Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2022

	2022			2021
Valuation assumptions
Expected dividend yield		0.0	%		0.0	%
Expected volatility		56.3% –70.7	%		70.0%-123.0	%
Expected term (years) – simplified method		3.0 – 6.1			5.5 – 6.1
Risk-free interest rate		2.04% – 3.0	%		0.95% – 1.16	%

Stock option activity during the nine months ended September 30, 2022 and 2021 is as follows:

Schedule of Stock Option Activity

	Number of Options			Weighted average exercise price		Weighted average remaining contractual term
Balance as of January 1, 2021		151,277		$	9.10		8.7
Granted		256,187			22.70
Additional options grant StemoniX holders		38,376			23.05
Options assumed in Merger		11,168			229.75
Exercised		(5,983	)		6.20
Forfeited		(18,217	)		19.10
Expired		(2,241	)		7.25
Balance as of September 30, 2021		430,567		$	23.80		8.8

Balance as of January 1, 2022		464,019			20.95		7.4
Granted		148,860			5.02
Exercised		(1,034	)		4.80
Forfeited		(94,364	)		14.94
Expired		(32,700	)		42.51
Balance as of September 30, 2022		484,781		$	15.34		8.2

Exercisable as of September 30, 2022		198,844		$	19.58		7.1

The Company recognized stock-based compensation related to different instruments for the three and nine months ended September 30 as follows:

		1		2		3		4
	For the three months ended September 30,				For the nine months ended September 30,
	2022		2021		2022		2021
Stock Options	$	162	$	117	$	559	$	805
Shares issued for services		143		10		306		20
Total	$	305	$	127	$	865	$	825
Share based compensation	$	305	$	127	$	865	$	825